Multi-column chromatography promises massive efficiency gains in downstream purification, but which platform actually delivers at commercial scale? As biologics manufacturers contend with intensified upstream outputs and shrinking facility footprints, continuous chromatography systems have moved from academic proof-of-concept into the GMP manufacturing suite. Selecting the right platform requires a hard look at resin utilization data, buffer consumption trade-offs, throughput constraints, and the operational complexity commercial teams will live with for a decade.
Key Takeaways
- Continuous chromatography systems, including BioSMB (Pall, a Danaher company), periodic counter-current chromatography (PCC, Cytiva), and simulated moving-bed continuous chromatography (SMCC) configurations, each deliver meaningful resin utilization improvements over batch capture but differ substantially in operational complexity and scale-up pathway. Platform selection should be driven by process-specific throughput targets and facility infrastructure, not vendor preference alone.
- Resin utilization gains of 50-80% over batch Protein A chromatography are achievable with multi-column continuous systems, directly reducing the cost of goods for high-titer mAb processes. These gains depend on accurate breakthrough curve characterization and disciplined column loading strategies validated at each scale.
- Buffer consumption reduction is a meaningful but often overstated benefit of continuous chromatography; actual savings are highly process- and resin-dependent, and facilities operating in-line dilution or concentrated buffer programs realize the largest downstream impact.
- Operational complexity in continuous chromatography is substantially higher than in batch operation: valve sequencing, column synchronization, and real-time UV and pressure monitoring all introduce failure modes that require robust automation and skilled operators to manage consistently in a GMP environment.
The Case for Continuous Chromatography in Commercial Biologics Manufacturing
The transition from batch to continuous chromatography is driven by a specific economic problem: high-titer fed-batch and perfusion processes routinely outpace the loading capacity of a single chromatography column operating in batch mode. At titers above 5 g/L, the column size required for batch Protein A capture becomes a capital and facility footprint constraint, and resin utilization in batch mode rarely exceeds 50-60% of dynamic binding capacity (DBC). Continuous chromatography systems address this directly by distributing the load across multiple columns operating in overlapping loading, washing, elution, and regeneration phases.
Working in analytical science?
Register for a FREE Separation Science account to subscribe to the Separation Science Newsletter.
The efficiency case is well-established in the literature. Landmark work published in Biotechnology and Bioengineering on integrated continuous production of recombinant therapeutic proteins demonstrated that continuous capture configurations, including PCC, deliver substantially higher resin productivity relative to batch Protein A operation at comparable purity outcomes. At production scales where Protein A resin cost represents a significant fraction of cost of goods sold, that productivity gain materially changes the financial model for each gram of product.
What differentiates platform selection at the commercial level is whether a specific platform integrates reliably with upstream output rates, existing automation infrastructure, and GMP documentation requirements without introducing unacceptable operational risk.
BioSMB Platform: Architecture and Commercial Performance
The BioSMB platform was developed by Tarpon Biosystems and acquired by Pall Corporation in 2015; Pall is now part of the Danaher life sciences portfolio. The system applies a simulated moving-bed principle adapted for biopharmaceutical capture steps, using a rotary valve architecture to direct feed, buffer, and eluate flows across multiple small-diameter columns in a carousel configuration. Rather than requiring complex manifold valve banks, the rotary valve cycles columns sequentially through loading and processing zones.
At commercial scale, BioSMB configurations typically operate with 4-16 columns, with column count and zone distribution determined by breakthrough curve kinetics and target productivity. The rotary valve design simplifies plumbing and reduces valve actuation events per cycle, which has practical implications for failure mode risk in a GMP environment. Pall has published process data showing resin utilization rates above 90% of DBC in optimized BioSMB configurations, compared with typical batch utilization of 50-65%. The primary limitation at commercial scale is column size: the rotary valve architecture constrains individual column diameter, and facilities requiring very large column volumes must run parallel BioSMB units rather than scaling a single system.
Periodic Counter-Current Chromatography: The Cytiva PCC Approach
Periodic counter-current chromatography (PCC), implemented in Cytiva's ÄKTA pcc platform, uses a two- or three-column configuration with flow-through UV detection at column outlet to determine real-time breakthrough and trigger column switching. The system loads feed onto a primary column until the UV signal at the outlet indicates approaching breakthrough, at which point feed switches to a freshly regenerated column while the loaded column enters washing and elution phases.
The three-column PCC format is the most widely adopted configuration for commercial biologics capture because it provides a continuous product stream while maintaining a buffer against upstream flow variations. The UV-triggered switching logic is readily validated and generates a clear audit trail for GMP documentation. Published data in the Journal of Chromatography A on twin-column CaptureSMB and related continuous Protein A processes has demonstrated resin productivity improvements of two- to three-fold relative to batch chromatography under optimized loading conditions.
PCC's relative operational simplicity makes it the most frequently implemented continuous chromatography format in current GMP commercial manufacturing. The configuration is compatible with standard ÄKTA automation infrastructure, and the UV breakthrough detection logic is well understood by downstream process engineers with batch chromatography experience. The trade-off is somewhat lower theoretical resin utilization than zone-distributed continuous systems like BioSMB, because each loading cycle leaves residual capacity unused at the breakthrough-triggered switch point.
SMCC Configurations and Alternative Multi-Column Approaches
Beyond BioSMB and PCC, several manufacturers and CDMOs operate custom simulated moving-bed continuous chromatography (SMCC) configurations built on programmable chromatography skids with multi-position valve manifolds. These systems use vendor-agnostic hardware (programmable logic controllers, multi-position valves, multiple chromatography columns) and run on custom process control software or standard chromatography software configured for multi-column operation.
SMCC configurations offer the highest theoretical flexibility: column count, zone distribution, and switching logic can be optimized independently for each process, enabling multi-step continuous purification schemes combining capture and polishing in a single integrated sequence. However, the engineering burden of building, validating, and maintaining a custom multi-column system in GMP is substantial. Validation of a custom automation configuration requires significantly more documentation effort than a platform system with an established regulatory submission history.
SMCC approaches are most appropriate for CDMOs or large-footprint manufacturers with dedicated automation engineering teams. For standard mAb Protein A capture at commercial scale, the operational overhead of a custom SMCC configuration rarely justifies the incremental performance advantage over PCC or BioSMB.
Platform Comparison: Resin Utilization, Throughput, and Buffer Consumption
The table below summarizes the key operational parameters differentiating the three main continuous chromatography platform approaches at commercial scale.
| Parameter | BioSMB | PCC (3-Column) | Custom SMCC |
|---|---|---|---|
| Typical resin utilization | 85-95% DBC | 70-85% DBC | 80-95% DBC |
| Column count | 4-16 | 2-3 | 3-12+ |
| Switching logic | Rotary valve (fixed zone) | UV breakthrough detection | Programmable valve manifold |
| Buffer consumption vs. batch | 20-40% reduction | 10-25% reduction | Process-dependent |
| Scale-up path | Parallel units | Larger column diameter | Custom engineering |
| GMP validation complexity | Moderate | Lower | Higher |
| Operational complexity | Moderate | Lower | Higher |
Buffer consumption reduction is frequently cited as a primary benefit, but actual savings vary significantly by process. Buffer volumes fall because smaller columns at higher resin utilization consume less equilibration and regeneration buffer per gram of product. For facilities that have implemented advanced bioprocess filtration and in-line buffer dilution strategies, buffer savings from continuous chromatography compound upstream buffer management improvements, substantially reducing WFI demand and buffer hold vessel requirements.
Scale-Up Parameters and Commercial Implementation Considerations
Translating a continuous chromatography process from development scale to commercial manufacturing introduces technical challenges distinct from batch scale-up. Beyond linear velocity and residence time, multi-column continuous systems require careful management of the column switching interval, loading fraction relative to breakthrough, inter-column wash volume, and the synchronization of multiple columns moving through different operational phases simultaneously.
Breakthrough curve characterization is the critical foundation of any continuous chromatography scale-up. Accurate characterization requires the same resin lot, feed stream composition, and operating temperature planned for commercial scale: deviations in feed titer, impurity profile, or pH can shift breakthrough behavior and invalidate loading parameters. Feed flow rate variation from upstream bioreactor or perfusion harvest streams can disrupt the synchronized column switching schedule, making surge vessel design and feed conditioning essential engineering considerations from the earliest stages of process design. As part of a broader approach to breaking the downstream bottleneck in continuous purification, this feed conditioning step deserves the same engineering rigor applied to the chromatography system itself.
Automation Requirements and GMP Process Control
Continuous chromatography in a GMP manufacturing environment requires a substantially more capable process control architecture than batch operation. The control system must simultaneously monitor UV, pressure, pH, and conductivity at multiple column positions, execute time- or trigger-based valve switching across complex manifold configurations, and manage exception handling for out-of-specification events without interrupting product collection.
PAT integration is particularly valuable in continuous chromatography. Real-time UV monitoring at multiple column positions provides data needed to detect early breakthrough, monitor washing completeness, and confirm elution pooling criteria without off-line sampling delays. The regulatory framework governing continuous manufacturing of therapeutic proteins is addressed in the ICH Q13 guidance on Continuous Manufacturing of Drug Substances and Drug Products, adopted by FDA in March 2023 and covering both small molecule and biologic contexts.
Resin Selection and Lifetime Validation for Continuous Operation
Not all chromatography resins perform equivalently in continuous multi-column operation. Beyond high static binding capacity and rapid mass transfer kinetics, continuous operation requires resins to maintain consistent dynamic binding capacity across the far higher cycle counts that accumulate rapidly in continuous mode. A resin that performs well for 50-100 batch cycles may show earlier capacity decline under the cycling frequency of a continuous process, where hundreds of equivalent batch cycles can accumulate over a single extended commercial run.
Column sanitization and resin lifetime validation strategies must account for the cycle count intensity of continuous operation. Accelerated lifetime studies using the commercial cycling frequency are essential for a defensible regulatory submission. The overall approach to downstream purification at commercial scale should integrate resin lifetime and cleaning validation planning from early process development to avoid late-stage regulatory gaps.
Selecting the Right Platform for Commercial Continuous Chromatography
Continuous chromatography delivers measurable efficiency gains across all three major platform approaches, but the platform that delivers the best outcome depends on factors specific to the process, the site, and the team. For organizations implementing continuous chromatography in a GMP manufacturing environment for the first time, PCC offers the most accessible entry point: the UV breakthrough switching logic is well understood, the column configuration is simple to validate, and regulatory precedent is broad, with the operational risk profile proportionally lower than more complex systems.
For manufacturers with established GMP automation capability and processes demanding the highest resin utilization and throughput, BioSMB or custom SMCC configurations offer superior performance at the cost of greater engineering complexity. The decision should be anchored in a quantitative process economics analysis accounting for resin cost per gram of product, buffer, and WFI consumption, capital cost, validation timeline, and the ongoing operational burden of managing a more complex system in a GMP environment. Platform selection is not a one-time optimization: it shapes every downstream process decision for the productive life of the manufacturing facility.
This article was produced under Separation Science's AI Editorial Guidelines.
